What Is Beta Hemolytic Streptococcus Group G?

Beta hemolytic streptococcus group G is a bacterium now formally known as Streptococcus dysgalactiae subspecies equisimilis (SDSE), and it causes a range of infections strikingly similar to those produced by its better-known relative, group A strep. For decades it was treated as a harmless bystander or a minor player, but research over the past twenty years has firmly established it as a genuine pathogen capable of causing everything from ordinary sore throats to life-threatening bloodstream infections and toxic shock syndrome. The story of group G strep is largely one of underestimation, and the science is still catching up.

What Organism Are We Talking About

When clinicians say “group G strep,” they are using the Lancefield classification system, which sorts streptococci by the carbohydrate antigens on their cell walls. Group G strep that causes human disease almost always belongs to a single subspecies: Streptococcus dysgalactiae subsp. equisimilis. This name was formally proposed in 1996 to distinguish the human disease-causing strains, which are beta-hemolytic and active against human proteins, from animal strains of the same parent species.¹ “Beta-hemolytic” means the bacteria completely destroy red blood cells on a lab plate, producing a clear zone around their colonies. This is the same hemolysis pattern seen in group A strep (Streptococcus pyogenes), the organism behind classic strep throat and scarlet fever.

A study that sequenced the genetic identity of 75 group G strep isolates from blood cultures of 66 patients found that every single one was SDSE.² In practical terms, if a lab report says a patient has group G strep in their blood, the organism is almost certainly SDSE. Other Lancefield group G species exist, but they rarely cause human infections.

How It Resembles Group A Strep

The resemblance between SDSE and Streptococcus pyogenes (group A strep) is not superficial. SDSE is described in the microbiological literature as “similar to Streptococcus pyogenes,” and both organisms cause infections of the throat and skin.³ One reason the two behave so similarly is that SDSE carries many of the same virulence genes. A study examining the genetic toolkit of group G SDSE isolates found that genes for streptolysin S, streptolysin O, hyaluronidase, laminin-binding protein, and C5a peptidase were present in virtually all strains tested.⁴ These are the same molecular weapons group A strep uses to break into tissues, destroy immune defenses, and spread through the body.

The overlap is not accidental. Genomic studies have shown that horizontal gene transfer, the process by which bacteria swap DNA, occurs regularly between SDSE and group A strep. One landmark finding demonstrated that the gene encoding M12 protein, a key surface molecule involved in immune evasion, has jumped between the two species.⁵ Broader genomic work has confirmed that this kind of gene swapping plays a major role in shaping the population structure of SDSE.⁶ Researchers have even identified a specific mobile genetic element in group G strep that can transfer itself not only to other group G isolates but also to group A and group B strep.⁷ This means group G strep is not just mimicking group A strep; the two are actively exchanging the genetic material that makes them dangerous.

Throat Infections That Look Like Strep Throat

One of the most practically relevant facts about group G strep is that it can cause pharyngitis (sore throat) that is clinically indistinguishable from classic group A strep throat. An outbreak at a college found that the illness, likely spread by respiratory droplets, produced fever, throat exudate, and swollen lymph nodes at rates matching typical group A strep pharyngitis.⁸ A study comparing patients with sore throats caused by group C or G strep to those with group A strep found that roughly 45% of the group C/G patients met the clinical criteria commonly used to diagnose bacterial pharyngitis, compared to 48% of group A patients. The researchers concluded that large-colony group C and G streptococci should be considered throat pathogens on the same level as group A strep.⁹

This matters because the standard rapid strep test used in most clinics only detects group A strep. If you have a sore throat caused by group G strep, the rapid test will come back negative, and your doctor might conclude you have a viral infection and send you home without antibiotics. In most cases of simple pharyngitis, that is probably fine; the throat infection resolves on its own. But in certain clinical situations, missing the diagnosis means missing an opportunity for treatment, and in rarer cases, it means not recognizing the pathogen before it causes deeper trouble.

Skin and Soft Tissue Infections

The skin is the single most common portal of entry for group G strep, especially in invasive disease. A study of group G strep bloodstream infections found that the skin was the source in about 62% of cases, with cellulitis being the most frequent clinical presentation, occurring in half of patients.¹⁰ On hospital wards, group G strep has been recovered from patients with pyoderma (skin infections with pus), erysipelas (a raised, sharply bordered skin infection), and phlegmon (a spreading soft-tissue infection). In one dermatology ward study, group G strep was found in 34 patients, the large majority of whom had active pyoderma or sepsis.¹¹

That same study highlighted something clinicians find frustrating about group G strep: a subset of patients carried the organism without obvious signs of infection. Six patients in the study had no clinical signs and were initially left untreated, but three of them later developed erysipelas within one to seven months.¹² The finding suggests that colonization without immediate symptoms does not always mean the organism is harmless.

Invasive Disease and Its Severity

Where group G strep truly earns its reputation is in invasive infections, meaning cases where the bacterium enters normally sterile sites like the bloodstream, joints, or heart valves. Group G strep accounts for roughly 3.5% of all patients with bloodstream infections caused by any bacterium, which sounds small until you consider the seriousness of those cases.¹³

Endocarditis, infection of the heart valves, is a particularly feared complication. In one series of fifteen patients with group G strep bacteremia, seven (47%) had endocarditis, with four deaths and four additional patients experiencing significant complications during long, difficult hospital stays.¹⁴ The course of group G endocarditis tends to be aggressive, in contrast to the slower, smoldering endocarditis caused by some other streptococcal species.¹⁵ A Canadian study of over 200 bacteremic events found that endocarditis occurred in about 18% of patients who received an echocardiogram, with native valve infection far more common than prosthetic valve involvement. Among those with endocarditis, the infection frequently spread to other organs, most often the lungs, skin, bones and joints, and brain. Sepsis occurred in 58% and toxic shock syndrome in half, with overall mortality at 17%.¹⁶

Streptococcal toxic shock syndrome (STSS) from group G strep, while uncommon, has been documented repeatedly. The clinical picture can be devastating: rapid-onset shock, organ failure, necrotizing soft-tissue infection, and death within days despite intensive care. A case report described a 79-year-old man with diabetes and leg swelling who developed shock and widespread tissue death of the lower leg within hours of admission; SDSE was confirmed from fluid aspirated from skin blisters, and the patient died on his third hospital day despite antibiotics and intensive care.¹⁷ A UK case series of three STSS patients caused by group G strep, all of whom survived, supports the point that this is a recognized complication, not a one-off oddity.¹⁸

Who Is Most Vulnerable

Invasive group G strep infections cluster overwhelmingly in older adults and people with chronic diseases. The median age in multiple studies falls in the late sixties to early seventies. One analysis proposed that the weakening of the immune system with age, sometimes called immunosenescence, represents the primary risk factor for group G strep infection, and that other conditions like cancer may simply be markers of an aging immune system rather than independent causes.¹⁹

Diabetes stands out as a risk factor with strong quantitative evidence behind it. A population-based study found that people with diabetes had about 2.6 times the risk of group G strep bloodstream infection compared to the general population. The risk climbed with poorer blood sugar control: those with well-managed diabetes had a modestly elevated risk, while those with poorly controlled disease had roughly 3.6 times the risk.²⁰ People with type 1 diabetes had a dramatically higher risk, though that estimate was based on a small number of cases.

Age also changes the way invasive group G strep disease presents. Among patients 60 and older, cardiovascular disease, chronic kidney disease, and confusion at presentation were more common. Among younger patients under 60, alcohol use and liver cirrhosis were significantly more frequent risk factors.²¹ The bottom line is that group G strep exploits weakened hosts, but the specific weakness varies by age.

Antibiotic Treatment and Resistance Concerns

Group G strep remains susceptible to penicillin, which is the treatment of choice for most infections, just as it is for group A strep. The organism has not developed meaningful penicillin resistance, and standard beta-lactam antibiotics work well in uncomplicated cases. Invasive infections typically require intravenous antibiotics and sometimes surgical intervention, particularly in necrotizing soft-tissue infections or endocarditis.

Where resistance has emerged is with macrolide and lincosamide antibiotics, the alternatives used in penicillin-allergic patients. A study from Spain found that 33% of group G strep isolates were resistant to erythromycin, which was actually a higher rate than for group A strep (26%) or group B strep (16%) in the same collection. Clindamycin resistance was also highest in group G strep at 33%.²² The mechanisms behind this resistance differ between streptococcal groups. In Finland, erythromycin-resistant group G strep isolates overwhelmingly carried a gene that modifies the bacterial ribosome, while erythromycin-resistant group C strep used a different mechanism based on drug efflux.²³

For clinicians, the practical takeaway is that penicillin or amoxicillin remains reliable, but if a patient cannot take penicillin and needs a macrolide or clindamycin, the lab should confirm susceptibility rather than assume it.

Diagnostic Challenges

Identifying group G strep in the lab is usually straightforward using traditional methods: the organism grows in large colonies, is beta-hemolytic, and reacts with group G antisera in a Lancefield grouping test. The challenge lies more in what happens before the lab. As mentioned, rapid antigen detection tests for strep throat only pick up group A, so group G strep pharyngitis is invisible to point-of-care testing.

Modern identification methods, including mass spectrometry (MALDI-ToF), have been evaluated for large-colony beta-hemolytic streptococci. One study found that MALDI-ToF correctly identified 94% of Streptococcus pyogenes isolates but only 66% of Streptococcus dysgalactiae isolates.²⁴ That gap means roughly a third of group G strep isolates were misidentified or not identified to the species level by the technology, which is increasingly used as the first-line identification method in hospital labs. Labs aware of this limitation may need supplementary testing to get the identification right, particularly in serious infections where the species matters for treatment decisions and prognosis.

Animal Reservoirs and Cross-Species Boundaries

Streptococcus dysgalactiae is not exclusively a human pathogen. The parent species infects cattle, horses, pigs, fish, and other animals, though different subspecies tend to be associated with different hosts. Whole-genome comparisons have shown that human and animal SDSE isolates cluster separately in phylogenetic analyses, with clear genetic boundaries between them.²⁵ This means that, in general, the strains infecting people are genetically distinct from those infecting animals.

The boundaries are not absolute, though. Research has identified specific virulence factors, including genes for fibronectin-binding protein and M protein, that appear to distinguish human-adapted from animal-adapted strains. Critically, these factors could be acquired by animal strains through horizontal gene transfer from human streptococci, potentially enabling animal strains to colonize human hosts.²⁶ This raises the theoretical concern that strains could jump from animals to humans, though documented cases of this happening remain rare. Given how freely these bacteria share DNA, the possibility is taken seriously by researchers studying the broader epidemiology of streptococcal disease.

Why Group G Strep Has Been Underestimated

Several factors have conspired to keep group G strep in the shadow of its group A cousin. Rapid tests do not detect it. Clinical guidelines for pharyngitis have historically focused exclusively on group A strep. Many older textbooks barely mention it, and laboratories sometimes report it without full species identification, lumping it in with “non-group-A beta-hemolytic streptococci” as though it were clinically unimportant. The organism was long classified as normal throat flora, which discouraged clinicians from treating it even when it showed up in symptomatic patients.

The accumulating evidence, including population-based studies documenting rising rates of invasive disease, documentation of toxic shock syndrome, and genomic work revealing the shared virulence arsenal with group A strep, has shifted the consensus. Researchers who study these infections have been explicit that SDSE should be recognized as an emerging pathogen. It frequently causes soft tissue and throat infections, and life-threatening invasive disease occurs most often in patients with serious underlying medical conditions.²⁷ The gap between what researchers know about group G strep and what many frontline clinicians realize about it is gradually closing, but it is still wider than it should be.